Skip to main content
Caplight Logo









VectorBuilder

VectorBuilder

Private
Chicago, IllinoisHealthcare & Life Scienceshttps://en.vectorbuilder.com/

Last Round

Series C

Extension

Jul 26, 2023

Est. Valuation

$1B

Total Funding Raised

$76M

Company Overview

VectorBuilder is a biotechnology company that provides a full spectrum of gene delivery solutions, including an online platform for vector design, custom cloning, virus packaging, and CDMO services for research and clinical applications.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Usage-Based SaaS

AI Layer

Infrastructure

Keywords

gene deliveryviral vectormolecular cloningCDMOcontract development and manufacturing organizationAAVadeno-associated virusGMP manufacturingcapsid engineeringCRISPR librarystable cell linesynthetic biologypreclinical testingbiotech outsourcinggene therapy tools

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

VectorBuilder Comparables

Compare VectorBuilder with similar companies based on industry and business-model similarity.

VectorBuilder comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
PackGene Biotech
88%
GenScript
84%
Charles River Laboratories
79%

VectorBuilder Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series C ExtensionJul 26, 2023
Series COct 1, 2022

VectorBuilder Investors

Notable investors and investment history

VectorBuilder investors
InvestorRounds
Legend CapitalSeries C
Guangzhou Yuexiu Industrial Investment Fund ManagementSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 3, 2026

    Attending the ARVO Annual Meeting in Denver, Colorado.

  • Apr 14, 2026

    Launched MuteFree AAV for gene therapy development.

VectorBuilder Filings

Explore SEC and related filing metadata, where available.

VectorBuilder filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about VectorBuilder's valuation, stock price, and market status.

Is VectorBuilder a public or private company?

VectorBuilder is a private company.

What is the current stock price of VectorBuilder?

VectorBuilder is a private company with no public stock price. No recent secondary market data is available.

How much is VectorBuilder worth (valuation)?

VectorBuilder's valuation is estimated at $1.0B based on funding round data.

Can I buy VectorBuilder stock?

VectorBuilder shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was VectorBuilder's last funding round?

VectorBuilder's most recent funding round was Series C Extension on July 26, 2023.

Who are the main investors in VectorBuilder?

Investor information for VectorBuilder is not publicly disclosed.

Will VectorBuilder IPO soon?

No public IPO plans have been announced for VectorBuilder.

How can I track VectorBuilder secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor VectorBuilder's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersChicago, Illinois
Employee Range105
Year Founded2014
Last FundingJul 26, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?